Lucrative Home business on Anti-Aging
Get paid for using Anti-Aging, Stem Cell treatment products and earn from the comforts of your own home.Do you get paid for referring a good movie or a good restaurant - NO ! But you do, when you use these products yourself and refer to your loved ones- HOW DIFFICULT IS THAT? log on now http://www.cellrenewals.jeunesseglobal.comFrom:CellrenewalsViews:0 0ratingsTime:03:12More inHowto Style
November 17, 2012 is Julie Meryls 3rd anniversary of her stem cell transplant. Her anniversary wish is for people to register to help save more lives at marrow.org. Giving marrow is not like you may imagine.
(PRWEB) November 15, 2012
If a person is lucky enough to be called by Be The Match, they can have the choice to not save a persons life if they are told the stem cells must be harvested via the bone. But remember, they may be the only chance for life for the patient. If a person is called for further testing, they may be this persons last chance to live.
My donor never questioned saving my life, JulieMeryl states. He is my hero! Please be a hero to the 70% of patients who never find a match.
Julie Meryl was diagnosed with Chronic Lymphocytic Leukemia at the age of 36. She was told to watch and wait, which actually means watch and worry until treatment is needed. All of Julie Meryls chemo cocktails failed. She needed a stem cell transplant to save her life. In November 2009, Julie Meryl went to Hackensack University Medical Center, located in New Jersey, for her transplant. A perfect match was found for her very quickly. Her donor is from Israel and even their blood type matches. Julie Meryl is still under care but is thrilled to be alive and excited to celebrate her big day on November 17, 2012.
Julie Meryl got through her journey with her sense of humor which can be found on some of her websites: leukemiasucks.com, badbloodclub.com, chemofarts.com.
For additional information contact Julie Meryl.
Contact information
Julie Meryl
juliemeryl.com
Stem Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy is a form of cell therapy that makes use of stem cells harvested from placenta for disease treatment. Stem cell therapy is also used for beauty, anti-aging and health rejuvenation purposes. The efficacy of stem cell therapy has been in practice for decades. Many rich and wealthy individuals and celebrities pay hefty price for stem cell therapy just to maintain youthfulness and vitality. For many severely ill-stricken people who have exhausted all means of conventional therapy look toward stem cell therapy for saving their condition and life. stemcellmalaysia.comFrom:stemcells2012Views:224 2ratingsTime:07:23More inHowto Style
Read the original:
Stem Cell Therapy | Stem Cell Malaysia - Video
David Kekich - Stem Cell Therapy Breakthrough
Centagen is developing technology to help millions of people who suffer from chronic pain, disease and injury with an advanced form of adult stem cell therapy. For more information go to http://www.indiegogo.comFrom:CentagenViews:325 118ratingsTime:02:35More inScience Technology
Follow this link:
David Kekich - Stem Cell Therapy Breakthrough - Video
What Areas of Arthritis Do Autologous Stem Cells Work Best For?
What types of conditions and what types of arthritis are most amenable to autologous stem cell treatment. Some joints do better than others. Why that is is still a matter of conjecture. It #39;s important to realize stem cells don #39;t work for every condition.From:Nathan WeiViews:0 1ratingsTime:02:00More inScience Technology
Here is the original post:
What Areas of Arthritis Do Autologous Stem Cells Work Best For? - Video
Conference explores Deaf identity and genetics - Remark! Deaf News
Remark! Deaf News - The best BSL Deaf News, presented in British Sign Language ( BSL ), for the latest Deaf news go to http://www.remark.uk.com 21st December 2011 Conference explores Deaf identity and genetics Last weekend, Bristol #39;s Centre for Deaf Studies hosted a conference that marked the end of a two year project focusing on genetics and the concept of Deafhood. Deafhood is a culturo-linguistic model that refers to the beliefs and practices of the Deaf community and people who use sign language, as well as their language, culture and history. The concept of Deafhood is the opposite of what is known as the #39;medical model #39; of deafness; that deafness is essentially something that should be fixed. The conference, called #39;Sleepwalking into Eugenics #39; arrived in the midst of a range of developments in deafness research, such as the stem cell treatment that has #39;cured #39; deafness in gerbils, that signals the possibility of deafness being #39;cured #39; in humans in the future. The conference was organised by Paddy Ladd and Steve Emery because they felt that the views of the Deaf community were being ignored in genetic research and to address this, they collected the views of Deaf people in individual interviews and group discussions across the UK. The project also looked at the views of hearing people and examined whether their perspective of Deaf people becomes more positive when they have seen the positive elements of Deaf culture for themselves. To do this, the project used a hearing ...From:RemarkLondonViews:0 0ratingsTime:03:45More inNews Politics
Originally posted here:
Conference explores Deaf identity and genetics - Remark! Deaf News - Video
LA JOLLA, Calif., Nov. 14, 2012 /PRNewswire/ --StemGenex, Inc. -- November is National Alzheimer's Disease Awareness Month and is dedicated to raising the awareness of this neurodegenerative disorder. Alzheimer's currently affects 5 million people in the U.S. and 35 million across the globe, and due to aging populations, this number is growing rapidly.
To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/stemgenex-on-the-forefront-of-adult-stem-cell-based-therapy-for-alzheimers-179326951.html
Currently pharmacological treatments only manage symptoms and offer no cure for the disease. Alternatively, adult stem cells have shown great promise to potentially replace lost or support damaged brain cells due to their remarkable ability of differentiating into many cell types.
StemGenex, a U.S. based company, is pioneering new therapeutic methods for adipose-derived adult stem cells. StemGenex has a major emphasis on Alzheimer's disease and other conditions such as Parkinson's, COPD, Multiple Sclerosis and Type 1 Diabetes. For over 6 years StemGenex has been conducting studies to advance Alzheimer's adult stem cell treatment protocols in efforts to alleviate the disease's symptoms. Some innovations at StemGenex include:
Rita Alexander, the President of StemGenex, says, "We are encouraged and excited with our progress in developing methods and protocols for adipose derived adult stem cell treatments for Alzheimer's disease."
Patients receiving treatment are reporting an alleviation of their symptoms which include:
Interestingly, scientific research studies have suggested that adult stem cells can provide both anti-inflammatory, regenerative functions, and immune-regulating properties, all of which could be neuroprotective. Outside their therapeutic potential are recent findings investigating the effects of adult stem cells on Alzheimer's. Remarkably, in this study the use of adult stem cells derived from humans could regenerate Alzheimer's disease brains of animal models.
We are on the brink of some tremendously exciting discoveries and developments in the use of adult stem cell based-therapies, for the treatment of Alzheimer's disease. Also, since adult stem cells can be isolated from an individual's own fat tissue there are no ethical or religious controversies.
To find out more about stem cell treatments contact StemGenex.
La Jolla Cove Research Center
Read more here:
StemGenex™ on the Forefront of Adult Stem Cell -Based Therapy for Alzheimer's
ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation. The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Gerons discontinued human embryonic stem cell programs. BioTime would contribute to BAC $5 million in cash, $30 million of BioTime common shares, warrants to purchase eight (8) million common shares of BioTime at a pre-specified price, rights to use certain human embryonic stem cell lines, and minority stakes in two of BioTimes subsidiaries. In addition, a private investor would invest $5 million in cash in BAC.
Following consummation of the potential transaction, Geron stockholders would receive shares representing 21.4% of the common stock of BAC as well as warrants to purchase 8 million shares of BioTime common stock at a pre-specified price. BioTime would own approximately 71.6%, and a private investor would own approximately 7.0% of the outstanding BAC common stock for their $5 million investment. BioTime would also receive warrants that would enable it to increase its ownership in BAC by approximately 2%, which would reduce the Geron stockholders ownership in BAC to 19.2%. BAC would also be committed to pay to Geron royalties on the sale of products that are commercialized in reliance upon Geron patents acquired by BAC.
The LOI is not a binding agreement to complete the transaction. Consummation of the transaction is necessarily subject to entering into a definitive agreement between the parties containing terms and conditions yet to be negotiated.
Kaye Scholer LLP and Thompson, Welch, Soroko & Gilbert LLP are acting as legal counsel to BioTime in connection with the acquisition of Gerons stem cell assets.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.
About BioTime Acquisition Corporation
BioTime Acquisition Corporation is a newly formed wholly owned subsidiary of BioTime, Inc., through which BioTime plans to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.
This communication is not an offer to sell any securities or a solicitation of any vote or approval and BioTime and BAC are not offering to sell, or soliciting an offer to buy, any securities in any state where the offer or sale is not permitted.
Visit link:
BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
Jonathan Milner, CEO of antibodies hothouse Abcam, has joined other angels in backing an exciting new stem cell company in Cambridge UK.
DefiniGEN is one of the first commercial opportunities to arise in the area of stem cells. The ability to generate stem cells by reprogramming cells from patients skin has revolutionised this area of research.
These cells, known as human induced pluripotent stem cells (hIPSC), can be differentiated into almost any cell type, allowing the opportunity to have a ready source of human cells for testing new therapies.
DefiniGEN has been formed to supply hIPSC-derived cells to the drug discovery and regenerative medicine sectors. The company is based on the research of Dr Ludovic Vallier, Dr Tamir Rashid and Professor Roger Pedersen of the Anne McLaren Laboratory of Regenerative Medicine.
The hIPSC-derived cells produced by DefiniGEN show many of the functional characteristics of primary cells, are highly reproducible and can be made in large quantities, making them ideal for liver toxicity testing, which is a major cause of drug candidate failure.
The universitys enterprise fund has also invested 50k in Inotec AMD a spin-out from the Department of Materials Science & Metallurgy, specialising in the treatment of chronic wounds.
Growing numbers of people, especially the elderly, suffer painful, debilitating wounds for five years or more. The treatment of these wounds consumes up to five per cent of total healthcare budgets.
The company is based on a combination of fuel cell technology developed by Professor Derek Fray and a novel system for distributing oxygen over a chronic wound.
Inotec has developed a portable, rechargeable battery powered oxygen generator about the size of smartphone which provides pure humidified oxygen using its own consumable oxygen delivery web.
As previously reported in Business Weekly, the enterprise fund made the first of its three investments to date in Cambridge CMOS Sensors (CCS) 125k.
The rest is here:
Abcam boss backs stem cell venture
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation
View post:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video